MR habitat radiomics for differentiating indeterminate (Grade 3) nasopharyngeal lesions: lymphoid hyperplasia versus early-stage nasopharyngeal carcinoma [0.03%]
用于区分鼻咽不确定期（3级）病变的磁共振成像影像组学：淋巴组织增生与早期鼻咽癌的区别诊断价值研究
Zhenhuan Huang,Xuezhao Tu,Qikui You et al.
Zhenhuan Huang et al.
Background: To investigate the feasibility of MRI-based habitat radiomics to differentiate indeterminate Grade 3 nasopharyngeal lesions into nasopharyngeal lymphoid hyperplasia or early-stage nasopharyngeal carcinoma, and...
Development and internal validation of a dynamic Prealbumin-Immune-Inflammation-NLR Prognostic Score (PINPS) for esophageal squamous cell carcinoma treated with immune checkpoint inhibitors: a retrospective cohort study [0.03%]
针对食管鳞癌免疫检查点抑制剂治疗的预后评分(PINPS)的开发和内部验证：一项回顾性队列研究
Huiping Ding,Shengnan Hao,Gengsheng He et al.
Huiping Ding et al.
Background: Immune checkpoint inhibitors improve survival in advanced esophageal squamous cell carcinoma (ESCC), yet many patients derive limited benefit, and identifying those at high risk of poor outcomes remains challe...
Risk stratification and cross-center prediction of thoracoabdominal 6D setup errors [0.03%]
胸腹腔六维摆位误差的风险分层及中心间预测
Weixiang Lin,Dongming Xie,Yongwen Fang et al.
Weixiang Lin et al.
Purpose: Thoracoabdominal CBCT-derived six-degree-of-freedom (6DoF) setup errors vary substantially across centers. Using record-level setup events as the unit of analysis, we examined whether pre-treatment workflow varia...
Recombinant zoster vaccine uptake and series completion among immunocompromised adults with cancer in the US [0.03%]
美国癌症患者中的免疫抑制成人水痘带状疱疹疫苗的接种及完成程序的情况
Justin Gatwood,Catherine McGuiness,Vasudha Gupta et al.
Justin Gatwood et al.
Purpose: To estimate recombinant zoster vaccine (RZV) use among adults with cancer since the 2021 US Advisory Committee on Immunization Practices (ACIP) recommendation to vaccinate immunocompromised adults aged ≥ 19 year...
Capmatinib and paclitaxel combination: a novel strategy for overcoming challenges in triple-negative breast cancer treatment [0.03%]
卡马替尼和紫杉醇联合用药：治疗三阴性乳腺癌的新型策略
Ahmad Habibian Sezavar,Fatemeh Fakhari,Emad Jafarzadeh et al.
Ahmad Habibian Sezavar et al.
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) with limited treatment options. Paclitaxel (PTX) is commonly used, but its effectiveness is hampered by resistance and metast...
Distinct genomic landscape of colorectal signet ring cell carcinoma reveals frequent KMT2 family alterations and SMAD4 inactivation [0.03%]
具有独特基因组图谱的结直肠印戒细胞癌常发生KMT2家族变异和SMAD4失活
Krittiya Korphaisarn,Jirapat Aiamsophon,Nuttapong Ngamphaiboon et al.
Krittiya Korphaisarn et al.
Background: Colorectal signet-ring cell carcinoma (SRCC) is a rare and highly aggressive subtype of colorectal cancer (CRC) associated with poor clinical outcomes. Despite its distinct pathology, colorectal SRCC remains u...
Curative-intent tri-modality treatment of de novo bone-only oligometastatic breast cancer: single-center patient outcomes [0.03%]
新发骨寡转移型乳腺癌的治愈意向三联治疗：单中心患者预后情况
Joseff Karl Fernandez,Georgia Harris,Boon Yang Jerome Leow et al.
Joseff Karl Fernandez et al.
Introduction: It is estimated that 10-25% of breast cancer patients have metastatic disease upon diagnosis with roughly 20% having limited metastatic sites. The optimal management of patients with de novo bone-only oligom...
NLR-based nomogram predicts survival in hepatocellular carcinoma treated with TACE plus targeted immunotherapy [0.03%]
基于NLR的预测肝癌接受TACE联合靶向免疫治疗生存结局的列线图
Hao-Ming Lan,Lin Chen,Shuo Yang et al.
Hao-Ming Lan et al.
Background: The neutrophil-to-lymphocyte ratio (NLR) has emerged as a potential prognostic biomarker in hepatocellular carcinoma (HCC), but its predictive value in patients with unresectable HCC receiving transarterial ch...
Clinicopathological and follow-up features of coexisting medullary and papillary thyroid cancer [0.03%]
合并髓样癌和乳头状癌的临床病理及随访特征分析
Chuqiao Liu,Cenkai Shen,Danni Liu et al.
Chuqiao Liu et al.
Objectives: Coexisting medullary and papillary thyroid cancer (MTC-PTC) are rare, and large-scale studies with sufficient sample sizes to delineate its distinct characteristics remain limited. ...
Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan [0.03%]
与接受德鲁替斯单抗治疗的晚期乳腺癌患者临床结局相关的基线外周血免疫标志物
Akihiro Fujimoto,Yuki Ichinose,Kazuo Matsuura et al.
Akihiro Fujimoto et al.
Background: Trastuzumab deruxtecan (T-DXd) has demonstrated substantial clinical efficacy in patients with advanced breast cancer; however, predictive and prognostic biomarkers for treatment outcomes remain poorly defined...